{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:42:25Z","timestamp":1779910945530,"version":"3.53.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejpb.2020.03.003","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:01:19Z","timestamp":1583496079000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy"],"prefix":"10.1016","volume":"150","author":[{"given":"Jingyao","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianya","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpb.2020.03.003_b0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.ejpb.2020.03.003_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.ejpb.2020.03.003_b0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ejpb.2020.03.003_b0020","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1021\/acsnano.8b01508","article-title":"Hierarchical multiplexing nanodroplets for imaging-guided cancer radiotherapy via DNA damage enhancement and concomitant DNA repair prevention","volume":"12","author":"Jiang","year":"2018","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.ejpb.2020.03.003_b0025","doi-asserted-by":"crossref","first-page":"18888","DOI":"10.1038\/s41598-019-54941-1","article-title":"Stochastic multicellular modeling of x-ray irradiation, DNA damage induction, DNA free-end misrejoining and cell death","volume":"9","author":"Forster","year":"2019","journal-title":"Sci. Rep."},{"issue":"5652","key":"10.1016\/j.ejpb.2020.03.003_b0030","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1126\/science.1088805","article-title":"Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha","volume":"302","author":"Hagen","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejpb.2020.03.003_b0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-08-0505","article-title":"Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia -inducible factor-1alpha","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejpb.2020.03.003_b0040","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1021\/acs.chemrev.6b00525","article-title":"Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia","volume":"117","author":"Liu","year":"2017","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.ejpb.2020.03.003_b0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejpb.2020.03.003_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccell.2014.10.015","article-title":"Dual-action combination therapy enhances angiogenesis while reducing tumor growthand spread","volume":"27","author":"Wong","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejpb.2020.03.003_b0055","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41565-019-0570-3","article-title":"Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies","volume":"14","author":"Sung","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"13","key":"10.1016\/j.ejpb.2020.03.003_b0060","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/0008-5472.CAN-18-2839","article-title":"Anti-CD24 antibody-nitric oxide conjugate (ANC) selectively and potently suppresses hepatic carcinoma","volume":"79","author":"Sun","year":"2019","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejpb.2020.03.003_b0065","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ncb1747","article-title":"Nitric oxide-induced nuclear GAPDH activates p300\/CBP and mediates apoptosis","volume":"10","author":"Sen","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"21","key":"10.1016\/j.ejpb.2020.03.003_b0070","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1158\/0008-5472.CAN-04-2212","article-title":"Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53","volume":"64","author":"Cook","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejpb.2020.03.003_b0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.cdd.4401181","article-title":"Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation","volume":"10","author":"Wang","year":"2003","journal-title":"Cell Death Differ."},{"issue":"44","key":"10.1016\/j.ejpb.2020.03.003_b0080","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1073\/pnas.1812704115","article-title":"Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth","volume":"115","author":"Arora","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2020.03.003_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.actbio.2019.10.002","article-title":"Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer","volume":"100","author":"Wei","year":"2019","journal-title":"Acta Biomater."},{"issue":"11","key":"10.1016\/j.ejpb.2020.03.003_b0090","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1021\/mp5003009","article-title":"Nitric oxide releasing d-alpha-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin","volume":"11","author":"Song","year":"2014","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.03.003_b0095","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7150\/thno.22711","article-title":"Recent advances in the application of vitamin E TPGS for drug delivery","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2020.03.003_b0100","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.2147\/IJN.S208089","article-title":"Regulating intracellular ROS signal by a dual pH\/reducing-responsive nanogels system promotes tumor cell apoptosis","volume":"14","author":"Dong","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.ejpb.2020.03.003_b0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2013.06.053","article-title":"Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS","volume":"454","author":"Xu","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2020.03.003_b0110","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/acs.molpharmaceut.7b00922","article-title":"Micelle system based on molecular economy principle for overcoming multidrug resistance and inhibiting metastasis","volume":"15","author":"Qi","year":"2018","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2020.03.003_b0115","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1021\/acs.nanolett.8b00495","article-title":"Intracellularly activatable nanovasodilators to enhance passive cancer targeting regime","volume":"18","author":"Deepagan","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2020.03.003_b0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2017.05.016","article-title":"Enhanced tumor therapy via drug co-delivery and in situ vascular-promoting strategy","volume":"258","author":"Yin","year":"2017","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.ejpb.2020.03.003_b0125","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/S1470-2045(16)30065-1","article-title":"Prophylactic cranial irradiation for patients with lung cancer","volume":"17","author":"Pechoux","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.03.003_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2016.69.9678","article-title":"Concurrent chemotherapy and radiation therapy for inoperable locally advanced non-small-cell lung cancer","volume":"35","author":"Rosenzweig","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ejpb.2020.03.003_b0135","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S1470-2045(14)70345-6","article-title":"High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer","volume":"15","author":"De Ruysscher","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.ejpb.2020.03.003_b0140","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.03.003_b0145","first-page":"990","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. Reply","volume":"380","author":"Antonia","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ejpb.2020.03.003_b0150","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.03.003_b0155","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.nanolett.8b04757","article-title":"Poly(amidoamine) dendrimer-coordinated copper(II) complexes as a theranostic nanoplatform for the radiotherapy-enhanced magnetic resonance imaging and chemotherapy of tumors and tumor metastasis","volume":"19","author":"Fan","year":"2019","journal-title":"Nano Lett."},{"issue":"6","key":"10.1016\/j.ejpb.2020.03.003_b0160","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1021\/acs.molpharmaceut.5b00129","article-title":"Enhance cancer cell recognition and overcome drug resistance using hyaluronic acid and alpha-tocopheryl succinate based multifunctional nanoparticles","volume":"12","author":"Liang","year":"2015","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2020.03.003_b0165","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1021\/nn5010815","article-title":"Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation","volume":"8","author":"Guo","year":"2014","journal-title":"ACS Nano"},{"issue":"6801","key":"10.1016\/j.ejpb.2020.03.003_b0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejpb.2020.03.003_b0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejpb.2020.03.003_b0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejpb.2020.03.003_b0185","unstructured":"C. KM, W. TJ, K. J, et al., The microenvironment of rapidly growing tumors is associated with increased energy demand and diminished vascular supply, hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12) (2002) 3387\u20133394."},{"issue":"8","key":"10.1016\/j.ejpb.2020.03.003_b0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Hx","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejpb.2020.03.003_b0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1535-6108(04)00118-7","article-title":"Intratumoral hypoxia, radiation resistance, and HIF-1","volume":"5","author":"Semenza","year":"2004","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ejpb.2020.03.003_b0200","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1269\/jrr.11056","article-title":"How can we overcome tumor hypoxia in radiation therapy?","volume":"52","author":"Harada","year":"2011","journal-title":"J. Radiat. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2020.03.003_b0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejpb.2020.03.003_b0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/cbt.2.3.373","article-title":"Histone H2AX in DNA damage and repair","volume":"2","author":"Sedelnikova","year":"2003","journal-title":"Cancer Biol. Ther."},{"issue":"24","key":"10.1016\/j.ejpb.2020.03.003_b0215","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.4161\/cc.5.24.3569","article-title":"GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence","volume":"5","author":"Sedelnikova","year":"2006","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.ejpb.2020.03.003_b0220","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","article-title":"GammaH2AX and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.ejpb.2020.03.003_b0225","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112030059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112030059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:36:33Z","timestamp":1760546193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112030059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":45,"alternative-id":["S093964112030059X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.03.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}